Can shared microbial antigens cause cross-reactive antibodies and discordant serology when PCR is negative?

Shared antigenic epitopes can cause antibody cross-reactivity, making multispecies serologic patterns difficult to interpret—especially when PCR is negative. This is most firmly demonstrated among related Borrelia species; it should not be assumed to establish a direct Borrelia–Mycoplasma pneumoniae antigenic relationship.

Clinical interpretation

• Cross-reactivity is a recognized source of false-positive or apparently discordant serology. Relapsing-fever Borrelia can yield false-positive Lyme antibody results, and relapsing-fever serology may cross-react across Borrelia species.
• Isolated reactivity to Borrelia targets such as OspC, BmpA, or VlsE1 is not species-level confirmation. OspC/BmpA bands alone are inadequate for Lyme diagnosis, and VlsE-containing assays require validated two-tier interpretation.
• A positive M. pneumoniae IgM with negative PCR is similarly nondiagnostic: IgM may persist after earlier infection, and assay-specific cross-reactivity can occur. This pattern does not establish coinfection.

Mechanistic basis

• Antibodies can recognize conserved or shared short epitopes rather than an entire protein. For Borrelia OspC, cross-reactivity tracked with similarity in residues 179–188; a shared B. afzelii/B. garinii epitope was mapped near residues 20–35.
• This is antigen- and epitope-specific. Conserved protein regions or simultaneous assay positivity do not by themselves demonstrate antibody cross-binding, and no direct evidence establishes shared cross-reactive epitopes between Borrelia and M. pneumoniae.

Meaning of negative PCR

• Negative PCR can coexist with antibody reactivity because PCR yield depends strongly on sampling time, disease stage, and specimen. Blood and CSF PCR are often low-yield for Lyme disease; relapsing-fever PCR is most useful early, and late M. pneumoniae sampling can also be PCR-negative.

Bottom line

• Discordant multispecies serology with negative PCR is compatible with cross-reactivity, persistent antibodies, and timing/specimen limitations—not proof of active concurrent infection. Clinical context, validated two-tier Borrelia testing, and, when warranted, paired repeat serology should guide interpretation.